Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Chronic Heart Failure | Reduced Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2021

Login to access report north_east
Contact sales account_box

Treatment of heart failure with reduced ejection fraction (HFrEF) is well established with a wealth of evidence from clinical trials that supports the use of all standard-of-care therapies for CHF. ACE inhibitors or AIIRAs, beta blockers, and loop diuretics are used for the first-line treatment of HFrEF patients. Branded agents—Novartis’s Entresto and Amgen’s Corlanor—are also approved for use in this CHF subpopulation. However, calcium-channel blockers are contraindicated in this population. The HFrEF Treatment Algorithm offers insight into prescribing patterns in CHF subpopulations with relatively established treatment guidelines.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed HF patients with reduced ejection fraction? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
  • How have Amgen’s Corlanor and Novartis’s Entresto been integrated into the treatment algorithm for HFrEF?
  • What proportion of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly?
  • What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of HFrEF patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated HFrEF patients?
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Heart Failure – Landscape & Forecast – Disease Landscape & Forecast (G7)
Heart failure (HF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (AHF) and…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east